MK-2060
Biological
Merck Sharp & Dohme Corporation
Total Payments
$1.7M
Transactions
161
Doctors
5
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $870,487 | 100 | 1 |
| 2019 | $786,069 | 61 | 5 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.6M | 150 | 98.2% |
| Consulting Fee | $28,250 | 6 | 1.7% |
| Travel and Lodging | $750.00 | 5 | 0.0% |
Payments by Type
Research
$1.6M
150 transactions
General
$29,000
11 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Single and Multiple Dose Clinical Trial to Study the Safety and Pharmacokinetics of MK-2060 in Older Participants with End-Stage Renal Disease on Hemodialysis | Merck Sharp & Dohme Corporation | $869,737 | 0 |
| Single and Multiple Dose Clinical Trial to Study the Safety andPharmacokinetics of MK-2060 in Older Participants with End-Stage Renal Disease on Hemodialysis | Merck Sharp & Dohme Corporation | $757,819 | 0 |
Top Doctors Receiving Payments for MK-2060
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Knoxville, TN | $1.6M | 150 |
| , M.D | Nephrology | Philadelphia, PA | $6,400 | 3 |
| , MD | Thoracic Surgery (Cardiothoracic Vascular Surgery) | Houston, TX | $5,650 | 2 |
| , MD | Vascular Surgery | San Francisco, CA | $5,650 | 2 |
| , M.D | Interventional Cardiology | Birmingham, AL | $5,650 | 2 |
| , MD | Nephrology | New York, NY | $5,650 | 2 |
Ad
Manufacturing Companies
Product Information
- Type Biological
- Total Payments $1.7M
- Total Doctors 5
- Transactions 161
About MK-2060
MK-2060 is a biological associated with $1.7M in payments to 5 healthcare providers, recorded across 161 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2019 to 2020. In 2020, $870,487 was paid across 100 transactions to 1 doctors.
The most common payment nature for MK-2060 is "Unspecified" ($1.6M, 98.2% of total).
MK-2060 is associated with 2 research studies, including "Single and Multiple Dose Clinical Trial to Study the Safety and Pharmacokinetics of MK-2060 in Older Participants with End-Stage Renal Disease on Hemodialysis" ($869,737).